ClinicalTrials.gg
CompletedNCT05963022Updated Oct 21, 2025Results posted

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

A Phase 3 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
20th of 43
206 · median 160
Started
2023
with 5 others
Phase 3
17 of 43
1 open now
Registered
29th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment, is one of 6 that started in 2023, is one of 17 in phase 3, and was the 29th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes
  • Have ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) despite diet and exercise treatment
  • Are of stable weight 5%) during the 90 days preceding screening and agree not to initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
  • Have (BMI) ≥23.0 kilogram per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes
  • Have a history of chronic or acute pancreatitis any time prior to study entry
  • Are currently receiving treatment for diabetic retinopathy and/or macular edema
  • Have a history of ketoacidosis or hyperosmolar state/coma
  • Have a history of Functional Classification IV congestive heart failure (CHF)
  • Have acute or chronic hepatitis including a history of hepatitis
  • Use of insulin 1-year preceding screening and between screening and baseline; use of any antihyperglycemic medication 90 days preceding screening and between screening and baseline.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    5 Milligram (mg) Tirzepatide

    Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks until the maintenance dose of 5 mg was reached.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg) until the maintenance dose of 10 mg was reached.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg) until the maintenance dose of 15 mg was reached.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received tirzepatide matched placebo administered as SC injection via a SDP QW for 40 weeks.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Percentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c \<7.0% (\<53 mmol/mol) is reported here.

    Time frame: Week 40

  2. Change From Baseline in Fasting Serum Glucose

    LS mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 40

  3. Percentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c ≤6.5% (≤48 mmol/Mol) is reported here.

    Time frame: Week 40

  4. Change From Baseline in Body Weight

    LS mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 40

  5. Percentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c \<5.7% (\<39 mmol/mol) is reported here.

    Time frame: Week 40

  6. Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

    The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS Mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.5%, \>8.5%) + Prior Antihyperglycemic Use + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 40

  7. Percentage of Participants Who Achieved Weight Loss of ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

    Time frame: Week 40

  8. Percentage of Participants Who Achieved Weight Loss of ≥10%

    Percentage of Participants who Achieved Weight Loss ≥10% is reported here.

    Time frame: Week 40

  9. Percentage of Participants Who Achieved Weight Loss of ≥15%

    Percentage of Participants who Achieved Weight Loss ≥15% is reported here.

    Time frame: Week 40

07

Results

Posted Oct 21, 2025

Participant flow

Participant flow — Overall Study
Milestone5 Milligram (mg) Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Started52515251
Received at least one dose of study drug52515251
Completed52464847
Not completed0544
Withdrew: Adverse event0110
Withdrew: Protocol violation0300
Withdrew: Pregnancy0111
Withdrew: Withdrawal by subject0021
Withdrew: Lost to follow-up0001
Withdrew: Subject required long-term initiation of rescue antihyperglycemic medication0001

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1c5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Hemoglobin A1c (HbA1c)-2.19 ± 0.121-1.75 ± 0.131-2.03 ± 0.124-0.77 ± 0.126
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.42 · 95% CI -1.76 to -1.07
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -0.98 · 95% CI -1.34 to -0.63
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.26 · 95% CI -1.61 to -0.92
SecondaryPercentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c \<7.0% (\<53 mmol/mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c Target Values of <7.0% (<53 Millimole/Mole [mmol/Mol])90.3886.3683.3338.30
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 17.04 · 95% CI 5.62 to 51.73
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.51 · 95% CI 2.77 to 20.37
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.24 · 95% CI 2.74 to 19.14
SecondaryChange From Baseline in Fasting Serum Glucose

LS mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligram per deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Fasting Serum Glucose-55.0 ± 3.00-54.8 ± 3.16-55.4 ± 3.06-30.2 ± 3.07
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -24.8 · 95% CI -33.3 to -16.3
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -24.6 · 95% CI -33.2 to -15.9
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -25.2 · 95% CI -33.7 to -16.7
SecondaryPercentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c ≤6.5% (≤48 mmol/Mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c Target Values of ≤6.5% (≤48 mmol/Mol)88.4675.0081.2523.40
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.61 · 95% CI 8.70 to 75.36
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.25 · 95% CI 2.88 to 18.25
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.95 · 95% CI 4.23 to 28.34
SecondaryChange From Baseline in Body Weight

LS mean was calculated using ANCOVA model with Baseline + Prior Antihyperglycemic Use + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Body Weight-6.1 ± 0.68-5.5 ± 0.71-8.7 ± 0.69-1.3 ± 0.70
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -4.8 · 95% CI -6.7 to -2.9
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -4.2 · 95% CI -6.2 to -2.3
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -7.3 · 95% CI -9.3 to -5.4
SecondaryPercentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Percentage of participants with HbA1c \<5.7% (\<39 mmol/mol) is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With HbA1c Target Values of <5.7% (<39 mmol/Mol)40.3834.0956.250
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 76.62 · 95% CI 4.40 to 1333.29
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 49.36 · 95% CI 2.80 to 868.67
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 118.22 · 95% CI 6.80 to 2055.04
SecondaryChange From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)

The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS Mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Baseline HbA1c (\<=8.5%, \>8.5%) + Prior Antihyperglycemic Use + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)
milligram per deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose Profiles (SMBG)-78.4 ± 3.959-78.3 ± 4.185-80.8 ± 4.186-33.9 ± 5.223
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -44.5 · 95% CI -57.5 to -31.5
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -44.3 · 95% CI -57.6 to -31.1
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -46.9 · 95% CI -60.1 to -33.7
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥5%

Percentage of Participants who Achieved Weight Loss ≥5% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥5%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥5%54.9066.6788.377.41
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 18.19 · 95% CI 5.27 to 62.73
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 30.96 · 95% CI 8.87 to 108.05
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 73.42 · 95% CI 19.36 to 278.40
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥10%

Percentage of Participants who Achieved Weight Loss ≥10% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥10%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥10%27.4533.3358.140
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.011 · Odds ratio (or): 39.04 · 95% CI 2.29 to 664.36
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.005 · Odds ratio (or): 56.34 · 95% CI 3.34 to 949.59
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 127.52 · 95% CI 7.58 to 2145.42
SecondaryPercentage of Participants Who Achieved Weight Loss of ≥15%

Percentage of Participants who Achieved Weight Loss ≥15% is reported here.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Weight Loss of ≥15%
percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss of ≥15%9.8013.3337.210
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.077 · Odds ratio (or): 13.86 · 95% CI 0.75 to 254.78
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.062 · Odds ratio (or): 15.65 · 95% CI 0.87 to 281.74
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.004 · Odds ratio (or): 66.69 · 95% CI 3.90 to 1140.13

Adverse events

Collected over Baseline up to week 44. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/52 (0%)5/52 (9.6%)41/52 (78.8%)
10 mg Tirzepatide0/51 (0%)6/51 (11.8%)44/51 (86.3%)
15 mg Tirzepatide0/52 (0%)3/52 (5.8%)45/52 (86.5%)
Placebo0/51 (0%)5/51 (9.8%)36/51 (70.6%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/231/200/250/22
Postmenopausal haemorrhageReproductive system and breast disorders1/230/200/250/22
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/520/510/520/51
Angina unstableCardiac disorders0/521/510/520/51
Arteriosclerosis coronary arteryCardiac disorders0/520/510/521/51
CataractEye disorders0/520/510/521/51
Optic ischaemic neuropathyEye disorders0/521/510/520/51
Abdominal painGastrointestinal disorders1/520/510/521/51
Large intestine polypGastrointestinal disorders0/521/511/520/51
Ankle fractureInjury, poisoning and procedural complications0/521/510/520/51
Most frequent other events
Showing 10 of 33
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
HyperglycaemiaMetabolism and nutrition disorders1/520/512/5217/51
DiarrhoeaGastrointestinal disorders12/5212/5115/520/51
Decreased appetiteMetabolism and nutrition disorders15/5213/5114/520/51
NauseaGastrointestinal disorders5/5211/5114/521/51
Upper respiratory tract infectionInfections and infestations11/529/519/5210/51
VomitingGastrointestinal disorders3/524/5110/520/51
Abdominal distensionGastrointestinal disorders8/526/516/521/51
HypertensionVascular disorders3/524/510/525/51
RegurgitationGastrointestinal disorders3/523/515/520/51
Injection site reactionGeneral disorders2/522/515/520/51

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean46.30 ± 11.3750.70 ± 10.7950.60 ± 12.1147.60 ± 11.5648.80 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female2320252290
Male29312729116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino52515251206
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native00000
Asian52515251206
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
China52515251206
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean8.07 ± 0.778.13 ± 0.787.97 ± 0.817.92 ± 0.678.02 ± 0.76
08

Study locations

28 sites
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • Shunde Hospital of Southern Medical Univesity
    Foshan, Guangdong 528399, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • Zunyi First People's Hospital
    Zunyi, Guizhou 563002, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan 473007, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Yichang Central People's Hospital
    Yichang, Hubei 443003, China
  • The First People's Hospital of Changde City
    Changde, Hunan 415003, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210012, China
  • Nanjing Medical University - Nanjing Jiangning Hospital
    Nanjing, Jiangsu 211100, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • Dalian University - The Affiliated Zhongshan Hospital
    Dalian, Liaoning 116001, China
  • Dalian Municipal Central Hospital Affiliated of Dalian Medical University
    Dalian, Liaoning 116033, China
  • Panjin Liaoyou Baoshihua Hospital
    Liaoyou, Liaoning 124009, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, Shaanxi 710077, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Pudong New Area People's Hospital Shanghai
    Shanghai, Shanghai Municipality 201200, China
  • Jiading District Central Hospital
    Shanghai, Shanghai Municipality 201800, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang 313000, China
09

References and documents

Publications

  • Yin Y, Ma J, Liu D, Duan W, Cheng Z, Jiang H, Zhang Y, Wu G, Zhuang H, Gu W, Mu Y. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Med. 2026 Jul 10;7(7):101183. doi: 10.1016/j.medj.2026.101183. Epub 2026 Jun 15. PubMed 42296968 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Oct 2024, 13 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Jul 27, 2023
StartActual
Aug 21, 2023
Primary completionActual
Oct 9, 2024
CompletionActual
Oct 9, 2024
Results first posted
Oct 21, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05963022
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Aug 21, 2023
Primary completion
Oct 9, 2024
Completion
Oct 9, 2024
Results posted
Oct 21, 2025
Last update
Oct 21, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion